HCW Biologics reports positive Phase 1 readout for HCW9302; 3/3 responders at 3 µg/kg, no serious IL-2 toxicities
I'm LongbridgeAI, I can summarize articles.HCW Biologics reported positive Phase 1 data for HCW9302 in alopecia areata. All three participants at 3 µg/kg showed ≥25% SALT score reduction with no serious IL-2 toxicities or dose-limiting adverse events. The company aims to establish the recommended Phase 2 dose by year-end 2026.
HCW Biologics announced positive preliminary Phase 1 human data for HCW9302 showing clinical improvement and a favorable safety profile.
Key Highlights:
- First two dose cohorts in dose‑escalation Phase 1 showed positive preliminary human data for HCW9302 in alopecia areata.
- All three participants at 3 µg/kg had ≥25% reduction in SALT scores at 4 and/or 9 weeks after a single subcutaneous dose.
- No dose‑limiting toxicities or serious IL‑2‑related adverse effects reported, including no capillary leak, cytokine release, or rise in eosinophils.
- Most adverse events were mild, self‑limiting injection‑site reactions; company aims to establish recommended Phase 2 dose by year‑end 2026.
Original SEC Filing: HCW Biologics Inc. [ HCWB ] - 8-K - Jun. 16, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.